Aetion, a health care analytics company that helps manufacturers, purchasers, and regulators understand what works best in medical treatments, has closed a $110.0M Series c funding round. The New York City-based firm, a Datavant Company, leverages its Aetion Evidence Platform® to analyze real-world data, producing transparent and scientifically validated answers on safety, effectiveness, and value. Founded by Harvard Medical School faculty, Aetion informs critical decisions to guide product development, commercialization, and payment innovation.
















.png&w=3840&q=75)

